FDA approved extending the age range for use of FluLaval Quadrivalent to include children 6 to 35 months of age
On Nov. 18, 2016, the U.S. Food and Drug Administration (FDA) approved extending the age range for use of FluLaval Quadrivalent, manuafactured by ID Biomedical, to include children 6 to 35 months of age.
Indications included active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Tags:
Source: U.S. Food and Drug Administration
Credit: